Clinical Development MilestonesVir anticipates sharing additional treatment data for chronic HDV infection, potentially setting a new standard for treatment efficacy.
Financial StabilityThe company has maintained a relatively stable capital position, ending the quarter with significant cash, equivalents, and investments.
Market OpportunityThe chronic hepatitis B virus infection market represents a substantial untapped opportunity, with the potential for significant aggregate revenues.